Financials data is unavailable for this security.
View more
Year on year Jacobson Pharma Corporation Ltd grew revenues 15.79% from 1.27bn to 1.47bn while net income improved 6.34% from 251.04m to 266.97m.
| Gross margin | 42.27% |
|---|---|
| Net profit margin | 14.32% |
| Operating margin | 22.70% |
| Return on assets | 4.74% |
|---|---|
| Return on equity | 8.23% |
| Return on investment | 5.76% |
More ▼
Cash flow in HKDView more
In 2024, cash reserves at Jacobson Pharma Corporation Ltd fell by 524.48m. However, the company earned 484.36m from its operations for a Cash Flow Margin of 33.00%. In addition the company generated 43.34m cash from investing, though they paid out 1.05bn more in financing than they received.
| Cash flow per share | 0.1833 |
|---|---|
| Price/Cash flow per share | 3.35 |
| Book value per share | 1.20 |
|---|---|
| Tangible book value per share | 0.9778 |
More ▼
Balance sheet in HKDView more
| Current ratio | 2.59 |
|---|---|
| Quick ratio | 1.73 |
| Total debt/total equity | 0.3159 |
|---|---|
| Total debt/total capital | 0.2382 |
More ▼
Growth rates in HKD
Year on year, growth in dividends per share increased 6.18% while earnings per share excluding extraordinary items growth only marginally increased 0.87%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 5.24% |
|---|---|
| Div growth rate (5 year) | 4.10% |
| Payout ratio (TTM) | 51.41% |
| EPS growth(5 years) | -2.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 0.8384 |
More ▼
